Key facts
- Tortugas Neuroscience’s last known valuation is $72.0M (Jun 2025).
- It has raised $30.0M; the latest was Seed Round ($29.0M) in Jun 2025.
- Notable investors include The Column Group.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Tortugas Neuroscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Tortugas Neuroscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tortugas Neuroscience
Developer of neurological therapeutics intended for rapid identification of efficacy and impact. The company focuses on identifying and advancing novel drug candidates through a scientific approach that integrates expertise in neurology and neuropsychiatry, enabling patients suffering from brain disorders to access treatments to improve quality of life.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Website
- tortugasneuro.com/
- Ownership
- Privately Held (backing)
Tortugas Neuroscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tortugas Neuroscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tortugas Neuroscience in its N-PORT filings yet. We sweep new filings monthly.